Overview

A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension

Status:
Completed
Trial end date:
2019-06-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of administration of azilsartan in pediatric patients aged 6 to less than 16 years with hypertension.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Azilsartan medoxomil